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Amongst the synthesized compounds, the best rounding up activity was obtained with 
compounds 11 and 19 (R1 = R2 = R3 = R6 = OCH3, R4 = R5 = H, R7 = OH) with concentrations 
of 0.13 and 0.2 µM, respectively. 
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Abstract 
 
To find new and better antivascular agents for cancer therapy, a series of combretastatin A4 
(CA4) analogues were prepared from 1,3-diaryl-2-nitroprop-1-enes (6-12) obtained in a two-step 
synthesis from appropriate arylaldehydes and 2-aryl-1-nitroethanes (4 or 5). Treatment of these 1,3-
diaryl-2-nitroprop-1-enes 6-12 by sodium azide in DMSO yielded the targeted compounds. The 
synthesized 1,2,3-triazoles disubstituted in 4- and 5-positions by one benzyl group and one aryl 
nucleus have also been tested for biological activities involved in antivascular action. It was found 
that several new compounds exhibited interesting biological activities in the nanomolar or low 
micromolar range, in terms of rounding up of endothelial cells, inhibition of tubulin polymerization, 
and cytotoxicity on B16 melanoma cancer cells. In silico docking studies of 11 and 19 within the 
active site of tubulin were also carried out in order to rationalize the inhibitory properties of these 
compounds and further understand their inhibition mechanism. In vivo evaluation of compounds 11 
and 19 in mice bearing colon 26 carcinoma indicated modest anticancer activity. 
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Amongst the synthesized compounds, the best rounding up activity was obtained with compounds 11 
and 19 (R1 = R2 = R3 = R6 = OCH3, R4 = R5 = H, R7 = OH) with concentrations of 0.13 and 0.2 µM, 
respectively. 
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1. Introduction 
Tumor vasculature is an attractive target for cancer therapy because solid tumors require 
blood vessels to grow and metastasize [1-4]. This requirement for neovascularization to allow 
tumors to grow beyond a certain threshold size drew attention to the potential therapeutic agents 
that may act on angiogenesis which occurs in several steps of the cancer process and offers several 
targets for intervention [1-10].  
Tumor vascularization is the result of pro-angiogenic factors and inhibitors and involves the 
interaction between endothelial cells and extracellular matrix. Various approaches have been 
developed to improve tumor control through the vascular targeting agents which can be divided into 
antiangiogenic and vascular-disrupting agents (VDAs) [11-14].  
Considering the VDAs [15, 16], the best active compounds that have been found to date are 
acting on tubulin polymerization. In this context, the molecule that emerged as one of the most 
potent is combretastatin A4 (CA4 1) which is a cis-stilbene derivative that was selected among 
seventeen combretastatin compounds originally isolated from the South African bushwillow tree 
Combretum caffrum Kuntze (Combretaceae) by Pettit and co-workers [17-19]. 
 
H3CO
H3CO OCH3 OCH3
OH CA4   1
 
 
CA4 (1) is a strong inhibitor of tubulin polymerization and can induce an important 
cytotoxicity in the nanomolar range against various cancer cell lines, including multi-drug resistant 
ones [20]. To be active, 1 requires the cis-configuration, but it is known that it can easily isomerize 
into its trans inactive form [21-22]. 
In order to stabilize the active configuration, numerous teams have synthesized a wide range 
of various cis-restricted analogues of 1. The literature has been repetitively reviewed during the past 
decade [23-32] and, among the wide range of published heterocyclic compounds, the triazole 
derivatives have received little attention. In this context, some 3,4-disubstituted 1,2,4-triazole [33, 
34], 1,4-disubstituted 1,2,3-triazole [35-38], 1,5-disubstituted 1,2,3-triazole [36-40] and 4,5-
disubstituted 1,2,3-triazole [40-42] showed interesting activities in terms of tubulin polymerization 
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inhibition and/or cytotoxicity. To our knowledge, only one report [37] deals with triazoles having 
vicinal benzyl and phenyl substituents (in the relative 1,5-positions) designed in order to confer to 
the molecule a higher degree of conformational freedom.  
In the context of hitherto unknown 1,2,3-triazoles disubstituted in the 4- and 5-positions by 
one aryl group and one benzyl substituent, the present study was undertaken to provide information 
on the biological activities of these compounds. We report here that several compounds of this 
series present interesting biological activities in the nanomolar or low micromolar range, in terms of 
rounding up of endothelial cells, inhibition of tubulin polymerization, and cytotoxicity on cancer 
cells. In silico docking studies of 11 and 19 within the active site of tubulin were also carried out 
and we also performed a preliminary in vivo evaluation of compounds 11 and 19 which revealed a 
modest anticancer activity in mice bearing colon 26 carcinoma tumors. 
 
2. Results and Discussion 
 
2.1. Chemistry 
 
The title compounds were prepared starting from 1,3-diaryl-2-nitroprop-1-enes (6-12) 
obtained according to a procedure already described by one of us [43] from appropriate 
arylaldehydes and some 2-aryl-1-nitroethanes (4 or 5) by refluxing in toluene in the presence of 
dimethylammonium chloride and a small amount of potassium fluoride. The required nitro 
derivatives 4 and 5 were synthesized by a two-step procedure starting from suitable benzaldehydes 
via the corresponding 2-aryl-1-nitroethenes (2 or 3, respectively), as depicted in Scheme 1.  
 
 
CHO
R1
R2
R3
CH3NO2, KF
R1
R2
R3
NO2 Na BH4
R1
R2
R3
NO2
Scheme 1
(CH3)2NH2+, Cl-
 Toluene, reflux
2 : R1 = OH, R2  = OCH3, R3 = H 4 : R1 = OH, R2  = OCH3, R3 = H
CHCl3, iPrOH, r. t.
3 : R1= R2 = R3 = OCH3 5 : R
1
= R2 = R3 = OCH3
 
 
 
Subsequent treatment of these 1,3-diaryl-2-nitroprop-1-enes 6-12 by sodium azide in 
dimethylsulfoxyde at 85°C, following a methodology reported by Quiclet-Sire and Zard [44], gave 
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the desired compounds as shown in Scheme 2, with good yield in most cases (cf. Experimental 
part). 
In a similar way, the indole derivative 21 has been prepared in 93% yield from the already 
known nitroethene 13 previously synthesized according to reference [43] (Scheme 3). 
The amino derivative 22 was easily obtained in 88% yield by catalytic hydrogenation in 
THF from its nitro precursor 17 as presented in Scheme 4. 
 
O2N
R7 R6
R5
R4
NaN3
DMSO, 85°C, 15 h
R1
R2
R3
R7
R6
N
N
HN
R5
14 : R1 = OH, R2  = OCH3, R3 = H   
R4 = H, R5 = OCH3, R6 = OCH3, R7 = OCH3
6 : R1 = OH, R2  = OCH3, R3 = H   
R4 = H, R5 = OCH3, R6 = OCH3, R7= OCH3
15 : R1 = OCH3, R2 = OCH3, R3 = OCH3
R4 = H, R5 = H, R6- R7 = OCH2O
16 : R1 = OCH3, R2 = OCH3, R3 = OCH3
R4 = Cl, R5  = H, R6 = Cl, R7 = H
17 : R1 = OCH3, R2 = OCH3, R3 = OCH3
R4 = H, R5  = H, R6 = OCH3, R7 = NO2
18 : R1 = OCH3, R2 = OCH3, R3 = OCH3
R4 = H, R5  = H, R6 = OCH3, R7 = F
19 : R1 = OCH3, R2 = OCH3, R3 = OCH3
R4 = H, R5  = H, R6 = OCH3, R7 = OH
11 : R1 = OCH3, R2 = OCH3, R3 = OCH3
R4 = H, R5  = H, R6 = OCH3, R7 = OH
20 : R1 = OCH3, R2 = OCH3, R3 = OCH3
R4 = H, R5 = H, R6 = OH, R7 = OCH3
8 : R1 = OCH3, R2 = OCH3, R3 = OCH3
R4 = Cl, R5  = H, R6 = Cl, R7 = H
9 : R1 = OCH3, R2 = OCH3, R3 = OCH3
R4 = H, R5  = H, R6 = OCH3, R7 = NO2
10 : R1 = OCH3, R2 = OCH3, R3 = OCH3
R4 = H, R5  = H, R6 = OCH3, R7 = F
7 : R1 = OCH3, R2 = OCH3, R3 = OCH3
R4 = H, R5  = H, R6- R7 = OCH2O
12 : R1 = OCH3, R2 = OCH3, R3 = OCH3
R4 = H, R5 = H, R6 = OH, R7 = OCH3
Scheme 2
R1
R2
R3
R4
 
 
 
OCH3
OCH3
OCH3
N
H
NO2
H3CO OCH3
OCH3HN
N
N
HN
21
NaN3
DMSO, 85°C, 15 h
13
Scheme 3
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H3CO
H3CO
OCH3
OCH3
NN
HN
NO2
H3CO
H3CO
OCH3
OCH3
NN
HN
NH2
2217
H2, Pd/C 10%
THF, RT, 1h
Scheme 4
 
The known compounds 23, 24 and 25 have been prepared from the appropriate 1,3-diaryl-2-
nitropropenes according to reference [43]. 
 
R1
R2
NO2
R3
R6
R5
R4
23 : R1 = OCH3, R2 = OCH3, R3 = OCH3
R4 = Cl, R5 = Cl, R6 = H
24 : R1 = OCH3, R2 = OCH3, R3 = OCH3
R4 = OCH3, R5 = OCH3, R6 = OCH3
25 : R1 = OCH3, R2 = OCH3, R3 = OCH3
R4 = OCH3, R5 = OH, R6 = OCH3
 
 
 
2. 2. Biological activities 
 
To evaluate the potential antivascular activity of the new cis-constrained analogues of 1, we 
first assessed their rounding up activity on endothelial cells, which is considered to be predictive of 
potential in vivo antivascular activity [45]. The compounds were also tested for their inhibition of 
tubulin polymerization and their cytotoxic activity on the murine B16 melanoma cell line. 
 
2.2.1. Morphological activity 
 
Table 1 presents the rounding up activity data for the synthesized combretastatin analogues 
from the most active to the less active compounds. Compared to the reference compound (1) which 
could elicit a rounding up of endothelial cells at very low concentrations (6 nM), seven compounds 
of our series showed interesting rounding up activity below 1 µM for a 2 hour exposure time (19, 
11, 22, 7, 6, 14 and 10). A representative photograph depicting the rounding up activity of 
compound 19 at a concentration of 1 µM is shown in Figure 1 and compared to CA4. It is 
noteworthy that rounding up activity was observed at concentration as low as 0.13 µM for 
compound 19. Alteration of endothelial cell morphology is a distinctive feature of the activity of 
VDAs which is correlated with cytoskeleton disorganization [45]. 
 
2.2.2. Tubulin polymerization inhibition 
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The compound concentrations needed to inhibit tubulin polymerization by 50% are also 
shown in Table 1. We observed that the best compounds for tubulin activity were also the ones that 
could elicit a rounding up of endothelial cells at low concentrations. It is noteworthy that a very 
good linear correlation exists between the inhibition of tubulin polymerization and the 
morphological activity (rounding up) on endothelial cells for the most active compounds presenting 
morphological activity at concentrations of less than 10 µM (Figure 2). 
 
2.2.3. Cytotoxicity 
 
Finally our new combretastatin analogues were also evaluated for their cytotoxicity on the 
B16 melanoma cell line. For this biological activity, the correlation with rounding up activity was 
less evident. With the exception of compounds 22, 14 and 18, which appear to be outliers, a relative 
good correlation was nonetheless observed between cytotoxicity and rounding up activity for the 
best morphologically active compounds (<10 µM). 
 
2.2.4. Structure-activity relationships 
 
Beside the well-known requirement of the 3,4,5-trimethoxyphenyl group for optimal 
biological activity of combretastatin analogues [21-30], we also noted the following interesting 
features for the new 4,5-disubstituted 1,2,3-triazoles and related 1,3-diaryl-2-nitroprop-1-enes. With 
regards to the nitroalkene and triazole series, we noted that the compounds the most similar to 1, 
i.e., those bearing a methoxyl group in the para position together with an hydroxy substituent in the 
meta position, were among the most potent derivatives (e.g., 19, 11, 6, 14). In this context, it must 
be pointed out that compounds belonging to series B, where the 3,4,5-trimethoxyphenyl nucleus is 
directly connected to the double bond of the triazole ring, are relatively less active compared to 
their analogues having a 3,4,5-trimethoxybenzyl substituent (compare 19 vs 14, 11 vs 6). 
Concerning the inversion of the relative position of methoxy and hydroxy groups (compare 
12 with 11 and 6, or 20 with 19 or 14) we noted that biological activities were noticeably 
diminished, in particular concerning tubulin polymerization inhibition. We also noted that the 
presence of a second methoxy group on the other meta position led to diminished biological activity 
(compare 25 vs 12). 
Although they remain slightly less efficient than 11 or 19, those derivatives in which the 
meta-hydroxy is replaced by a fluorine atom (10 or 18), a nitro group (9 or 17) or an amino 
substituent (22) led, particularly in this latter case, to fairly good results (NH2 > F > NO2).  
However, the replacement of the 4-methoxy-3-hydroxybenzene nucleus by a 3,4-
methylenedioxybenzene (compare 11 to 7 and 19 to 15), by a 3,4,5-trimethoxybenzene (compare 11 
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to 24), by dichlorobenzenes (compare 11 to 8 or 23 and 19 to 16) or by a 3-indolyl (compare 6 to 
13 and 14 to 21) were found unfavorable to biological activities. 
Finally, with the exception of the couple 11/19 where the measured biological activities are 
very close, the comparison between the nitroalkene series (6-13) and the triazole compounds (14-
22) demonstrates that the nitroalkenes 6-13, having a higher degree of conformational freedom, are 
more active than their corresponding triazole derivatives. 
Considering the relatively good in vitro activities of compounds 11 and 19 in terms of 
cytotoxicity, rounding up of endothelial cells and inhibition of tubulin polymerization, the putative 
mechanism of action of these compounds is probably close to that of CA4. 
 
2.3. Molecular modeling 
 
 In order to compare the putative binding mode of our cis-constrained analogues of CA4 and 
combretastatin itself, docking studies were carried out by using the reported high-resolution crystal 
structure of the tubulin-DAMA-colchicine(CN-2) complex (PDB ID: 1SA0) [46] as it was done on 
other heterocyclic analogues of CA4 [47]. The colchicine site, well described in two recent reviews 
[48, 49], is a deep pocket located at the α−β interface of tubulin heterodimers. Massaroti et al. [49] 
identified three zones of interaction reproduced in Figure 3. The trimethoxyphenyl ring (TMP or A 
ring) of CN-2 lies in a hydrophobic pocket of zone 2 while the other side of the molecule (C ring) 
interacts in zone 1 by van der Waals contacts. Furthermore two residues are highlighted as they are 
often involved in hydrogen bond interactions with ligands: Cys241 β and Val181 α. It should be 
noted that the residue numbering system we used is derived from the crystal structure [46]. 
 Docking simulations were performed with GOLD software version 5.1 [50] (see docking 
protocol for more details). Our protocol was validated by its ability to reproduce the crystal 
complex structure CN-2 / tubulin by docking the ligand extracted from the complex. 
Superimposition, not shown, of our best docked pose on the crystal structure gave an RMSD 
deviation, based on heavy atoms, of 0.92 Å. The C ring is involved in hydrogen bond with Val181 
α. The TMP ring is at a good distance of Cys241 β to be involved in hydrogen bond, but the polar 
hydrogen atom of cystein is not properly directed to the methoxy oxygen atoms of CN-2. 
 The next step was the docking of CA4. The conformer with the lowest energy resulting from 
a conformational analysis was chosen as starting point. The pose, corresponding to the best docking 
score of the 100 conformations generated during the docking process, is superimposed to CN-2 
crystal structure (Figure 3). It exhibits a similar binding mode, where the TMP rings are buried in 
the same hydrophobic pocket and, where the oxygen atom of the hydroxyl group is involved in 
hydrogen bond with Val 181 α, in accordance with the C ring of CN-2. 
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 Initial structures of 11 and tautomers of 19 were prepared similarly to CA4. The best 
docked poses were then selected to be superimposed, on Figure 3, on the CA4 conformation 
previously obtained. 11 docked in a very similar position relative to CA4, establishing again a 
hydrogen bond with Val 181 α. Although the oxygen acceptor atoms of nitro group are close to the 
hydrogen atoms of Ala 250 β or Asp251 β, our model does not exhibit such hydrogen bonds.  
 Among the three tautomers of 19, we can distinguish the one were hydrogen is on the 
central nitrogen. It adopts a CN2-like pose but not in the top 10 of scored conformations. In this 
case, not shown, the triazole group points its hydrogen atom to the amino group of Asn101 α 
without favorable interaction. The two other tautomers poses differ only by the hydrogen atom 
position. In the first case, not shown, this hydrogen interacts via a hydrogen bond with the carbonyl 
group of Asn258 β. In the second case, represented on Figure 3, the hydrogen is at the opposite side 
of the ring and is not involved in a hydrogen bond. It should be noted that the poses of those two 
last tautomers have a very similar score. The three tautomers have in common the pockets, where 
their aromatic rings are embedded but shifted regarding those of CA4. This shift result is the loss of 
hydrogen bond with Val 181 α. 
 To conclude, we observed the non-coplanar cisoid arrangement of the two aromatic rings, 
highlighted on Figure 3, of CA4 and its analogues. This arrangement is described as essential for 
the biological activity [51], but it is not sufficient because the loss of some hydrogen bonds and the 
absence of new ones could explain the lower biological activity than the one observed with CA4. 
 
 
2.4. Evaluation of antitumor activity in colon 26-bearing mice 
 
Based on their good in vitro biological activities, compounds 11 and 19 were selected for 
further in vivo testing in colon 26 tumor bearing mice. The colon 26 tumor was chosen because this 
model is responsive to antivascular agents [52]. Figure 4 presents the tumor volume of controls 
receiving the solvent and treated animals receiving compound 11 or 19 at their highest non toxic 
dose, i.e., 150 mg/kg for 11 and 100 mg/kg for 19, administered intraperitoneally for two weeks on 
days 3-7 and 10-14 after tumor implantation (day 0). Compounds 11 and 19 presented similar 
percent T/C values of 52% and 60%, respectively, measured when control tumors reached 1500 
mm3. The tumor growth delay of treated mice compared to controls (T-C) was 2 days for compound 
11 and 2.7 days for compound 19.  
Although 11 and 19 caused a significant delay in tumor growth, this antitumor efficacy can 
be regarded as modest activity considering that a T/C value of 42% is considered the minimum 
level for activity according to the National Cancer Institute criteria. It is however possible that other 
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schedules of administration and/or doses could contribute to improve the antitumor activity of 
these compounds. 
 
 
3. Conclusion 
 
We have, for the first time to our knowledge, synthesized new 1,2,3-triazoles disubstituted in 4- and 
5-positions by one benzyl and one aryl groups. We also evaluated these new compounds for 
potential antivascular and anticancer activities and found that several compounds presented 
interesting biological activities, e.g., rounding up of endothelial cells (at concentrations in the 
submicromolar range), inhibition of tubulin polymerization and cytotoxicity on B16 cancer cells (at 
concentrations in the low micromolar range). In silico docking studies of 11 and 19 within the 
active site of tubulin were also carried out in order to rationalize the inhibitory properties of these 
compounds and further understand their inhibition mechanism. In addition, the evaluation of 
compounds 11 and 19 in tumor bearing mice indicated modest in vivo anticancer activity. 
 
 
4. Experimental protocols 
 
4.1. Synthesis 
 
 
Melting points were measured on a Köfler hot stage apparatus and are uncorrected. Mass 
spectra were recorded on a Waters ZQ 2000 system using electrospray ionization (ESI) or on a 
Waters LCT apparatus for High-resolution mass spectra (HRMS - ESI). Infrared spectra were 
obtained using an FT-IR Perkin-Elmer spectrometer as chloroform solutions or KBr discs. NMR 
spectra were recorded with a Bruker ACP 300 spectrometer at 300 MHz for 1H NMR and 75 MHz 
for 13C NMR. Chemical shifts are expressed as parts per million downfield from tetramethylsilane. 
Splitting patterns have been designated as follows: s (singlet), d (doublet), dd (doublet of doublet), 
m (multiplet), br. (broad signal). Coupling constants (J values) are listed in hertz (Hz). Reactions 
were monitored by analytical thin layer chromatography and products were visualized by UV light. 
Merck Silica gel (230-400 Mesh ASTM) was used for column chromatography. Methanol and 
CH2Cl2 employed as eluents were distilled on a rotary evaporator prior to use. Dry THF was 
prepared by distillation from benzophenone/sodium. 
 
4.1.1 General procedure 1 for the synthesis of 2-aryl-1-nitroethenes 2 and 3. 
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To a solution of the corresponding arylaldehyde in toluene were added nitromethane (11 
equivalents), dimethylamine hydrochloride (4 equivalents) and potassium fluoride (0.15 
equivalents). The flask was equipped with a Dean-Stark and the mixture was heated at reflux 
temperature until the disappearance of the arylaldehyde (usually noted after a reaction time of 4-5 
hours). After being cooled at room temperature, the reaction mixture was evaporated under vacuum 
to eliminate the toluene, then diluted with water and extracted by CH2Cl2 (3x). In some cases, a 
filtration over Celite surface was required in order to eliminate excess reagent or reaction residues 
prior to extraction. The organic phase was then washed with water, dried over MgSO4, filtered and 
concentrated under vacuum. Crude product was purified by chromatography on silica gel in order to 
afford the desired compound. 
4.1.1.1  2-(3-Hydroxy-4-methoxyophenyl)-1-nitroethene (2). 
General procedure 4.1.1. was applied to iso-vanillin (3-hydroxy-4-methoxybenzaldehyde) 
(46.0 g, 0.30 mol) with a reaction time of 3 h. The crude product was purified by chromatography 
on silica gel (CH2Cl2 100%) to provide the corresponding 2-aryl-1-nitroethene as an ocher-colored 
solid, which was afterwards recrystallized to afford bright orange crystals (30.0 g, 0.154 mol, 51%). 
Mp: 161-162 ºC (heptane/benzene); 1H-NMR (300 MHz, CDCl3): δ = 3.97 (s, 3H, OCH3), 5.73 (s, 
1H, OH), 6.90 (d, J = 9.4 Hz, 1H, H-5’), 7.07 (d, J = 1.9 Hz, 1H, H-2’), 7.12 (dd, J1 = 9.4 Hz, J2 = 
1.9 Hz, 1H, H-6’), 7.48 (d, J = 12.6 Hz, 1H, =CH-1), 7.92 (d, J = 12.6 Hz, 1H, =CH-2); 13C-NMR 
(75 MHz, DMSO): δ = 56.5 (CH3, OCH3), 112.6 (CH, C-2’), 116.18 (CH, C-5’), 124.4 (CH, C-6’), 
128.7 (C, C-1’), 136.1 (CH, C-1), 140.4 (CH, C-2), 147.5 (C, C-3’), 152.3 (C, C-4’); IR (NaCl): υ’ 
3542 (OH), 3023 (=C-H), 1616 (C=C), 1508 (NO2 as), 1340 (NO2 ss), 1275 (Ar-O), 1133 (C-O) 
cm-1; MS (ESI(-)): m/z 194 [M-1H]. Anal calcd for C9H9NO4: C: 55.39; H: 4.65; N: 7.18. Found C: 
55.51; H: 4.55; N: 7.29. 
4.1.1.2.  2-(3,4,5-Trimethoxyphenyl)-1-nitroethene (3) [43]. 
Mp: 124-125 ºC (isopropanol); 1H-NMR (300 MHz, CDCl3): δ = 3.67 (s, 9H, OCH3-C3’, OCH3-C4’, 
OCH3-C5’), 6.75 (s, 2H, H-2’, H-6’), 7.53 (d, J = 14.4 Hz, 1H, =CH-2), 7.93 (d, J = 14.4 Hz, 1H, 
=CH-1); 13C-NMR (75 MHz, CDCl3): δ =: 56.3 (CH3 x 2, OCH3-C3’, OCH3-C5’), 61.1 (CH3, OCH3-
C4’), 106.5 (CH x 2, C-2’, C-6’), 125.3 (CH, C-2), 136.4 (C, C-1’), 139.3 (CH, C-1), 153.7 (C x 3, 
C-3’, C-4’, C-5’); IR (NaCl): υ’ 3021 (=C-H), 1633 (C=C), 1503 (NO2 as), 1328 (NO2 ss), 1244 
(Ar-O), 1130 (C-O) cm-1; MS (ESI(+)): m/z 262 [M+Na]+
. 
Anal calcd for C11H13NO5: C: 55.23; H: 
5.48; N: 5.86. Found C: 55.42; H: 5.35; N: 5.97. 
 
4.1.2. General procedure 2 for the synthesis of 2-aryl-1-nitroethanes 4 and 5. 
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To a flask containing the corresponding 2-aryl-1-nitroethene were added silica gel (2 
grams per mmol of starting material), and 1.5 mL of 2-propanol and 8 mL of chloroform per gram 
of silica gel [53]. To this mixture were added 4 mmol of NaBH4 per mmol of starting material in 
small amounts and the resulting mixture was allowed to stir at room temperature until the complete 
disappearance of the 2-aryl-1-nitroethene (usually noted after a reaction time of about 30 minutes). 
The reaction mixture was quenched with an aqueous solution of 0.1 N HCl, filtered to eliminate the 
silica gel and evaporated under vacuum to eliminate 2-propanol and chloroform. The resulting 
aqueous mixture was then extracted by CH2Cl2 (3x). The organic phase was dried over MgSO4, 
filtered and concentrated under vacuum. Crude product was purified by chromatography on silica 
gel in order to afford the desired compound. 
 
4.1.2.1.  2-(3-Hydroxy-4-methoxyphenyl)-1-nitroethane (4). 
 
General procedure 4.1.2. was applied to 2 (10 g, 50.0 mmol) with a reaction time of 30 
minutes. The crude product was purified by chromatography on silica gel (CH2Cl2) to provide the 
corresponding 2-aryl-1-nitroethane as pale yellow needles (6.92 g, 35.1 mmol, 68%).Mp: 52-53 ºC 
(pentane); 1H-NMR (300 MHz, CDCl3): δ =: 3.21 (t, J = 7.7 Hz, 2H, CH2-2), 3.96 (s, 3H, OCH3), 
4.56 (t, J = 7.7 Hz, 2H, CH2-1), 5.62 (s, 1H, OH), 6.67 (dd, J1 = 8.4 Hz, J2 = 2.1 Hz, 1H, H-6’), 6.77 
(d, J = 2.1 Hz, 1H, H-2’), 6.78 (d, J = 8.4 Hz, 1H, H-5’); 13C-NMR (75 MHz, CDCl3): δ = 33.9 
(CH2, C-2), 55.8 (CH3, OCH3), 76.7 (CH2, C-1), 110.9 (CH, C-5’), 114.7 (CH, C-2’), 120.3 (CH, C-
6’), 128.6 (C, C-1’), 145.8 (C, C-3’), 145.9 (C, C-4’); IR (NaCl): υ’ 3541 (OH), 1555 (NO2 as), 
1380 (NO2 ss), 1273 (Ar-O), 1029 (C-O) cm-1; MS (ESI(+)): m/z 220 [M+Na]+. C9H11NO4: C: 
54.82; H: 5.62; N: 7.10. Found C: 55.01; H: 5.59; N: 7.21. 
 
4.1.2.2.  2-(3,4,5-Trimethoxyphenyl)-1-nitroethane (5). 
 
General procedure 4.1.2. was applied to 3 (20 g, 83.6 mmol) with a reaction time of about 
30 minutes. The crude product was purified by chromatography on silica gel (CH2Cl2 100%) to 
provide the corresponding 2-aryl-1-nitroethane as white fluffy crystals (19.05 g, 79.0 mmol, 94%). 
Mp: 84-85 ºC (cyclohexane/benzene/); 1H-NMR (300 MHz, CDCl3): δ = 3.24 (t, J = 8.0 Hz, 2H, 
CH2-2), 3.80 (s, 3H, OCH3-C4’), 3.85 (s, 6H, OCH3-C3’, OCH3-C5’), 4.59 (t, J = 8.0 Hz, 2H, CH2-1), 
6.37 (s, 2H, H-2’, H-6’); 13C-NMR (75 MHz, CDCl3): δ = 33.8 (CH2, C-2), 56.0 (CH3 x 2, OCH3-
C3’, OCH3-C5’), 60.7 (CH3, OCH3-C4’), 76.5 (CH2, C-1), 105.6 (CH x 2, C-2’, C-6’), 131.4 (C, C-
1’), 153.5 (C x 3, C-3’, C-4’, C-5’); IR (NaCl): υ’ 1555 (NO2 as), 1349 (NO2 ss), 1240 (Ar-O), 
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1131 (C-O) cm-1; MS (ESI(+)): m/z 264 [M+Na]+. C11H15NO5: C: 54.77; H: 6.27; N: 5.81. Found 
C: 54.89; H: 6.08; N: 5.90. 
 
4.1.3. General procedure for the synthesis of 1,3-diaryl-2-nitropropenes 6 - 12, 23 - 25. 
 
To a solution of the corresponding 2-aryl-1-nitroethane in xylene were added dimethylamine 
hydrochloride (2 equivalents), potassium fluoride (0.2 equivalents) and the appropriate arylaldehyde 
(1 equivalent). The flask was equipped with a Dean-Stark and the mixture was heated at reflux 
temperature until the disappearance of the arylaldehyde (usually noted after a reaction time of 24 
hours). After being cooled at room temperature, the reaction mixture was evaporated under vacuum 
to eliminate the xylene, then diluted with water and extracted by CH2Cl2 (3x). The organic phase 
was then washed with water, dried over MgSO4, filtered and concentrated under vacuum. Crude 
product was purified by chromatography on silica gel in order to afford the desired compound [43]. 
Compounds 7, 8, 11, 12, 23, 24, and 25 are already described in ref [43]. 
 
4.1.3.1.  3-(3-Hydroxy-4-methoxyphenyl)-1-(3,4,5-trimethoxyphenyl)-2-nitropropene (6). 
 
General procedure 4.1.3. was performed with 3,4,5-trimethoxybenzaldehyde (6.47 g, 33.0 
mmol) and 4 (5.91 g, 30.0 mmol) with a reaction time of 24 h. The crude product was purified by 
chromatography on silica gel (CH2Cl2/acetone 99/1) to provide the corresponding 1,2-
diarylnitroethene together with excess benzaldehyde, which was afterwards eliminated by treatment 
with Girard’s T reagent [54]. The expected compound was obtained as a yellow solid and was then 
recrystallized from a mixture hexane/benzene to provide bright yellow crystals (5.91 g, 15.7 mmol, 
52%). Mp: 95-96 ºC (hexane/benzene); 1H-NMR (300 MHz, CDCl3) δ  = 3.70 (s, 3H, OCH3-C4"), 
3.82 (s, 6H, OCH3-C3", OCH3-C5"), 4.20 (s, 2H, CH2-C1), 5.55 (s, 1H, OH), 6.66 (s, 2H, H-2", H-
6"), 6.70 (s, 1H, H-2'), 6.80-6.81 (m, 2H, H-5', H-6'), 8.24 (s, 1H, H-2). 13C-NMR (75 MHz, 
CDCl3): δ = 32.6 (CH2, CH2-Ar), 56.4 (CH3 x 3, OCH3-C3’, OCH3-C4’, OCH3-C5’), 80.9 (CH3, 
OCH3-C4”), 107.6 (CH x 2, C-2’, C-6’), 110.9 (CH, C-6”), 114.1 (CH, C-5”), 118.7 (CH, C-2”), 
127.2 (CH, C-2), 129.4 (C, C-1’), 136.0 (C, C-1”), 140.0 (C, C-1), 145.5 (C, C-3”), 145.9 (C, C-4”), 
148.7 (C, C-4’), 153.7 (C x 2, C-3’, C-5’); IR (NaCl): υ’ 3541 (OH), 3023 (=C-H), 1592 (C=C), 
1554 (NO2 as), 1379 (NO2 ss), 1272 (Ar-O), 1130 (C-O) cm-1; MS (ESI(+)): m/z 398 [M+Na]+. 
C19H21NO7: C: 60.79; H: 5.64; N: 3.73. Found C: 60.84; H: 5.65; N: 3.78. 
 
4.1.3.2.  1-(4-Methoxy-3-nitrophenyl)-3-(3,4,5-trimethoxyphenyl)-2-nitropropene (9). 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 14 
General procedure 4.1.3. was performed with 4-methoxy-3-nitrobenzaldehyde (5.80 g, 
32.0 mmol) and 5 (7.60 g, 31.5 mmol) with a reaction time of 24 h. The crude product was purified 
by chromatography on silica gel (CH2Cl2/acetone 99/1) to provide the corresponding 1,2-
diarylnitroethene as a yellow solid, which was afterwards recrystallized to provide bright yellow 
crystals (6.78 g, 16.8 mmol, 53%). Mp: 158-159 ºC (heptane/benzene); 1H-NMR (300 MHz, 
CDCl3): δ = 3.80 (s, 6H, OCH3-C3’, OCH3-C5’), 3.82 (s, 3H, OCH3-C4’), 4.01 (s, 3H, OCH3-C4”), 
4.21 (s, 2H, CH2-Ar), 6.39 (s, 2H, H-2’, H-6’), 7.15 (d, J = 9.1 Hz, 1H, H-5”), 7.62 (dd, J1 = 9.1 Hz, 
J2 = 2.0 Hz, 1H, H-6”), 8.01 (d, J = 2.0 Hz, 1H, H-2”), 8.26 (s, 1H, =CH-2); 13C-NMR (75 MHz, 
CDCl3): δ = 33.1 (CH2, CH2-Ar), 56.1 (CH3 x 2, OCH3-C3’, OCH3-C5’), 56.8 (CH3, OCH3-C4’), 60.8 
(CH3, OCH3-C4”), 104.6 (CH x 2, C-2’, C-6’), 114.3 (CH, C-5”), 121.2 (C, C-1”), 124.2 (CH, C-
2”), 131.1 (CH, C-6”), 132.6 (C, C-1’), 135.6 (CH, C-2), 137.2 (C, C-3”), 149.8 (C, C-1), 153.7 (C 
x 3, C-3’, C-4’, C-5’), 154.3 (C, C-4”); IR (NaCl): υ’ 3021 (=C-H), 1592 (C=C), 1535 (NO2 as), 
1329 (NO2 ss), 1240 (Ar-O), 1130 (C-O) cm-1; MS (ESI(+)): m/z 427 [M+Na]+. C19H20N2O8: C: 
56.43; H: 4.99; N: 6.93. Found C: 56.54; H: 5.01; N: 7.02. 
 
4.1.3.3.  1-(3-Fluoro-4-methoxyphenyl)-3-(3,4,5-trimethoxyphenyl)-2-nitropropene (10). 
 
General procedure 4.1.3. was performed with 3-fluoro-4-methoxybenzaldehyde (2.50 g, 16.2 
mmol) and 5 (3.50 g, 14.6 mmol) with a reaction time of 24 h. The crude product was purified by 
chromatography on silica gel (CH2Cl2/acetone 99/1) to provide the corresponding 1,2-
diarylnitroethene as an orange solid, which was afterwards recrystallized to afford bright ocher-
colored fine crystals (1.77 g, 4.7 mmol, 32%). Mp: 126-128 ºC (heptane/benzene); 1H-NMR (300 
MHz, CDCl3): δ = 3.80 (s, 6H, OCH3-C3’, OCH3-C5’), 3.83 (s, 3H, OCH3-C4’), 3.93 (s, 3H, OCH3-
C4”), 4.22 (s, 2H, CH2-Ar), 6.39 (s, 2H, H-2’, H-6’), 6.98-7.03 (m, 1H, H-5”), 7.23-7.30 (m, 2H, H-
2”, H-6”), 8.23 (s, 1H, =CH-2); 13C-NMR (75 MHz, CDCl3): δ = 33.1 (CH2, CH2-Ar), 56.1 (CH3 x 
2, OCH3-C3’, OCH3-C5’), 56.3 (CH3, OCH3-C4’), 60.8 (CH3, OCH3-C4”), 104.5 (CH x 2, C-2’, C-6’), 
113.5 (CH, J = 7.2 Hz, C-5”), 117.4 (CH, J = 20.1 Hz, C-2”), 124.5 (C, J = 7.2 Hz, C-1”), 127.3 
(CH, C-2), 131.5 (CH, C-6”), 134.6 (C, C-1’), 137.0 (C, C-1), 149.8 (C, J = 20.1 Hz, C-4”), 152.2 
(C, J = 246.8 Hz, C-3”), 153.6 (C x 3, C-3’, C-4’, C-5’); IR (NaCl): υ’ 3022 (=C-H), 1613 (C=C), 
1513 (NO2 as), 1329 (NO2 ss), 1240 (Ar-O),1131 (C-O) cm-1; MS (ESI(+)): m/z 400 [M+Na]+. 
C19H20FNO6: C: 60.47; H: 5.34; N: 3.71. Found C: 60.66; H: 5.29; N: 3.67. 
 
4.1.4. General procedure for the synthesis of 4-benzyl-5-phenylriazoles 14 - 22 
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To a solution of the corresponding benzylphenylnitroethene in DMSO (minimum volume: 
approximately 10 mL for 3 mmol) was added NaN3 (2 equivalents) [42]. The resulting mixture, 
which acquired a dark red color right after the addition, was allowed to stir at 85 ºC under argon 
atmosphere until complete conversion of the starting material (usually noted after a reaction time of 
15 hours). After being cooled at room temperature, the reaction mixture was diluted with water and 
then extracted by CH2Cl2 (4x). The organic phase was dried over MgSO4, filtered and concentrated 
under vacuum. Crude product was purified by chromatography on silica gel. In order to eliminate 
remaining DMSO, the evaporated fractions containing the desired compound were dissolved in 
ether and washed with water (3x), dried over MgSO4, filtered and then concentrated under reduced 
pressure.  
 
4.1.4.1. 4-(3-Hydroxy-4-methoxybenzyl)-5-(3,4,5-trimethoxyphenyl)-1,2,3-triazole (14). 
 
General procedure 4.1.4. was applied to 6 (1.13 g, 3.0 mmol) with a reaction time of 12 h. 
The crude product was purified by chromatography on silica gel (CH2Cl2/MeOH 95/5) and then 
treated to eliminate remaining DMSO according to general procedure 4 to provide the expected 
compound as a white foamy solid (0.94 g, 2.53 mmol, 84%). Mp: 82-83 ºC (heptane/benzene); 1H-
NMR (300 MHz, CDCl3): δ = 3.77 (s, 6H, OCH3-C3’, OCH3-C5’), 3.64 (s, 3H, OCH3-C4’), 3.66 (s, 
3H, OCH3-C4”), 4.18 (s, 2H, CH2), 5.80 (bs, 1H, OH), 6.65 (dd, J1 = 8.5 Hz, J2 = 2.0 Hz, 1H, H-
6”’), 6.76 (d, J = 8.5 Hz, 1H, H-5”’), 6.78 (d, J = 2.0 Hz, 1H, H-2”), 6.81 (s, 2H, H-2’, H-6’); 13C-
NMR (75 MHz, CDCl3): δ = 30.6 (CH2, CH2-Ar), 56.1 (CH3 x 3, OCH3-C3’, OCH3-C4’, OCH3-C5’), 
60.9 (CH3, OCH3-C4”), 104.8 (CH x 2, C-2’, C-6’), 111.0 (CH, C-5”), 114.8 (CH, C-2”), 119.7 (CH, 
C-6”), 125.9 (C, C-5), 131.3 (C, C-1’), 138.0 (C, C-4), 145.5 (C, C-3”), 146.0 (C, C-4”), 153.4 (C x 
3, C-3’, C-4’, C-5’); IR (NaCl): υ’ 3541 (OH), 3009 (NH), 1590 (C=C), 1239 (Ar-O), 1129 (C-O) 
cm-1; HRMS (ESI): m/z 372.1577 [M+H]+, C19H22N3O5 requires 372.1559 
 
4.1.4.2.  5-(Benzo-[1,3]-dioxol-5-yl)-4-(3,4,5-trimethoxybenzyl)-1,2,3-triazole (15). 
 
General procedure 4.1.4. was applied to 2-(benzo-[1,3]-dioxol-5-yl)-1-(3,4,5-
trimethoxybenzyl)-1-nitroethene (7) (1.00 g, 2.7 mmol) with a reaction time of 6 h. The crude 
product was purified by chromatography on silica gel (CH2Cl2/MeOH 95/5) and then treated to 
eliminate remaining DMSO according to general procedure 4.1.4 to provide the expected compound 
as a light brown foamy solid (0.96 g, 2.60 mmol, 96%). Mp: 153-154 ºC (heptane/benzene); 1H-
NMR (300 MHz, CDCl3): δ = 3.76 (s, 6H, OCH3-C3’, OCH3-C5’), 3.81 (s, 3H, OCH3-C4’), 4.14 (s, 
2H, CH2-Ar), 5.99 (s, 2H, CH2-O), 6.39 (s, 2H, H-2’, H-6’), 6.85 (d, J = 7.7 Hz, 1H, H-7”), 7.06 (d, 
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J = 2.1 Hz, 1H, H-4”), 7.09 (dd, J1 = 7.7 Hz, J2 = 2.1 Hz, 1H, H-6”); 13C-NMR (75 MHz, 
CDCl3): δ = 31.3 (CH2, CH2-Ar), 55.9 (CH3 x 2, OCH3-C3’, OCH3-C5’), 60.9 (CH3, OCH3-C4’), 
101.3 (CH2, CH2-O), 105.5 (CH x 2, C-2’, C-6’), 108.3 (CH, C-4”), 108.6 (CH, C-7”), 121.6 (CH, 
C-6”), 124.0 (C, C-5”), 134.1 (C, C-1’), 136.4 (C, C-5), 142.0 (C, C-4), 147.7 (C, C-3”a), 147.9 (C, 
C-7”a), 153.2 (C x 3, C-3’, C-4’, C-5’); IR (NaCl): υ’ 3009 (NH), 1592 (C=C), 1240 (Ar-O), 1130 
(C-O) cm-1; HRMS (ESI): m/z 370.1414 [M+H]+, C19H20N3O5 requires 370.1403 
 
4.1.4.3.  5-(2,4-Dichlorophenyl)-4-(3,4,5-trimethoxybenzyl)-1,2,3-triazole (16). 
 
General procedure 4.1.4. was applied to 2-(2,4-dichlorophenyl)-1-(3,4,5-trimethoxybenzyl)-
1-nitroethene (8) (1.00 g, 2.5 mmol) with a reaction time of 12 h. The crude product was purified by 
chromatography on silica gel (CH2Cl2/MeOH 95/5) and then treated to eliminate remaining DMSO 
according to general procedure 4 to provide the expected compound as an orange solid (0.96 g, 2.43 
mmol, 97%). Mp: 127-128 ºC (heptane/benzene); 1H-NMR (300 MHz, CDCl3): δ = 3.74 (s, 6H, 
OCH3-C3’, OCH3-C5’), 3.76 (s, 3H, OCH3-C4’), 3.98 (s, 2H, CH2), 6.25 (s, 2H, H-2’, H-6’), 7.18 (d, 
J = 9.1 Hz, 1H, H-6”), 7.25 (dd, J1 = 9.1 Hz, J2 = 1.8 Hz, 1H, H-5”), 7.48 (d, J = 1.8 Hz, 1H, H-3”); 
13C-NMR (75 MHz, CDCl3): δ = 31.2 (CH2, CH2-Ar), 56.8 (CH3 x 2, OCH3-C3’, OCH3-C5’), 60.9 
(CH3, OCH3-C4’), 105.9 (CH x 2, C-2’, C-6’), 127.1 (CH, C-3”), 128.3 (C, C-5), 129.6 (CH, C-6”), 
132.7 (CH, C-5”), 133.6 (C, C-4), 134.7 (C, C-1”), 135.5 (C, C-2”), 136.3 (C, C-4”), 152.0 (C x 3, 
C-3’, C-4’, C-5’); IR (NaCl): υ’ 3009 (NH), 1593 (C=C), 1239 (Ar-O), 1121 (C-O), 754 (C-Cl) cm-
1; HRMS (ESI): m/z 370.1414 [M+H]+, C18H1835Cl2N3O3 requires 394.0730. 
 
4.1.4.4.  5-(4-Methoxy-3-nitrophenyl)-4-(3,4,5-trimethoxybenzyl)-1,2,3-triazole (17). 
 
General procedure 4.1.4. was applied to 9 (1.68 g, 4.15 mmol) with a reaction time of 6 h. 
The crude product was purified by chromatography on silica gel, using a gradient of MeOH in 
CH2Cl2 from 99/1 to 95/5 as eluent, and then treated to eliminate remaining DMSO according to 
general procedure 4 to provide the expected compound as a yellow foamy solid, which was 
afterwards recrystallized to afford bright orange fine crystals (0.60 g, 1.5 mmol, 36%). Mp: 165-166 
ºC (benzene/acetonitrile); 1H-NMR (300 MHz, CDCl3): δ = 3.80 (s, 6H, OCH3-C3’, OCH3-C5’), 3.82 
(s, 3H, OCH3-C4’), 4.00 (s, 3H, OCH3-C4”), 4.19 (s, 2H, CH2-Ar), 6.44 (s, 2H, H-2’, H-6’), 7.14 (d, 
J = 9.4 Hz, 1H, H-5”), 7.88 (dd, J1 = 9.4 Hz, J2 = 1.5 Hz, 1H, H-6”), 8.13 (d, J = 1.5 Hz, 1H, H-2”); 
13C-NMR (75 MHz, CDCl3): δ = 31.6 (CH2, CH2-Ar), 56.1 (CH3 x 2, OCH3-C3’, OCH3-C5’), 56.7 
(CH3, OCH3-C4’), 60.9 (CH3, OCH3-C4”), 105.5 (CH x 2, C-2’, C-6’), 113.9 (CH, C-5”), 123.3 (C, 
C-1”), 124.6 (CH, C-2”), 132.9 (C, C-5), 133.2 (CH, C-6” + C, C-1’), 136.8 (C, C-3”), 139.5 (C, C-
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4), 152.9 (C, C-4”), 153.5 (C x 3, C-3’, C-4’, C-5’); IR (NaCl): υ’ 3017 (NH), 1592 (C=C), 1508 
(NO2 as), 1353 (NO2 ss), 1239 (Ar-O), 1129 (C-O) cm-1; HRMS (ESI): m/z 401.1470 [M+H]+, 
C19H21N4O6 requires 401.1461. 
 
4.1.4.5.  5-(3-Fluoro-4-methoxyphenyl)-4-(3,4,5-trimethoxybenzyl)-1,2,3-triazole (18). 
 
General procedure 4.1.4. was applied to 10 (1.00 g, 2.63 mmol) with a reaction time of 12 h. 
The crude product was then purified by chromatography on silica gel (CH2Cl2/MeOH 99.5/0.5) and 
then treated to eliminate remaining DMSO according to general procedure 4 to provide the expected 
compound as a light brown solid (0.53 g, 1.42 mmol, 54%). Mp: 115-117 ºC (heptane/benzene); 1H-
NMR (300 MHz, CDCl3): δ = 3.74 (s, 6H, OCH3-C3’, OCH3-C5’), 3.79 (s, 3H, OCH3-C4’), 3.89 (s, 
3H, OCH3-C4”), 4.14 (s, 2H, CH2-Ar), 6.38 (s, 2H, H-2’, H-6’), 6.94-6.99 (m, 1H, H-5”), 7.30-7.39 
(m, 2H, H-2”, H-6”); 13C-NMR (75 MHz, CDCl3): δ = 31.4 (CH2, CH2-Ar), 56.0 (CH3 x 2, OCH3-
C3’, OCH3-C5’), 56.3 (CH3, OCH3-C4’), 60.8 (CH3, OCH3-C4”), 105.5 (CH x 2, C-2’, C-6’), 113.5 
(CH, J = 6.9 Hz, C-5”), 115.5 (CH, J = 20.3 Hz, C-2”), 123.4 (C, J = 6.9 Hz, C-1”), 123.6 (CH, J = 
3.7 Hz, C-6”), 133.7 (C, C-1’), 136.6 (C x 2, C-4, C-5), 147.7 (C, J = 20.3 Hz, C-4”), 152.3 (C, J = 
244.1 Hz, C-3”), 153.3 (C x 3, C-3’, C-4’, C-5’); IR (NaCl): υ’ 3011 (NH), 1591 (C=C), 1239 (Ar-
O), 1130 (C-O) cm-1; HRMS (ESI): m/z 374.1527 [M+H]+, C19H21FN3O4 requires 374.1516. 
 
4.1.4.6. 4-(3,4,5-Trimethoxybenzyl)-5-(3-hydroxy-4-methoxyphenyl)-1,2,3-triazole (19). 
 
General procedure 4.1.4. was applied to 11 (1.13 g, 3.0 mmol) with a reaction time of 12 h. 
The crude product was purified by chromatography on silica gel (CH2Cl2/MeOH 95/5) and then 
treated to eliminate remaining DMSO according to general procedure 4 to provide the expected 
compound as a whitish foamy solid (0.94 g, 2.53 mmol, 84%). Mp: 82-83 ºC (heptane/benzene); 
1H-NMR (300 MHz, CDCl3): δ = 3.75 (s, 6H, OCH3-C3’, OCH3-C5’), 3.79 (s, 3H, OCH3-C4’), 3.90 
(s, 3H, OCH3-C4”), 4.17 (s, 2H, CH2), 5.35 (br. s, 1H, OH), 6.43 (s, 2H, H-2’, H-6’);  6.88 (d, J = 
8.3 Hz, 1H, H-5”), 7.11 (dd, J1 = 8.3 Hz, J2 = 1.2 Hz, 1H, H-6”), 7.22 (br. s, 1H, H-2’’); 13C-NMR 
(75 MHz, CDCl3): δ = 32.0 (CH2, CH2-Ar), 56.5 (CH3 x 3, OCH3-C3’, OCH3-C4’, OCH3-C5’), 60.8 
(CH3, OCH3-C4”), 106.4 (CH x 2, C-2’, C-6’), 113.2 (CH, C-5”), 115.4 (CH, C-2”), 119.1 (CH, C-
6”), 124.8 (C, C-5), 135.5 (C, C-1’), 136.6 (C, C-1’’), 142.7 (C, C-3’’), 144.6 (C, C-4), 147.5 (C, C-
4”), 153.6 (C x 2, C-3’, C-5’); IR (NaCl): υ’ 3541 (OH), 3009 (NH), 1590 (C=C), 1239 (Ar-O), 
1129 (C-O) cm-1; HRMS (ESI): m/z 372.1578 [M+H]+, C19H22N3O5 requires 372.1559 
 
4.1.4.7. 4-(3,4,5-trimethoxybenzyl)-5-(4-Hydroxy-3-methoxyphenyl)-1,2,3-triazole (20). 
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General procedure 4.1.4. was applied to 12 (1.13 g, 3.0 mmol) with a reaction time of 14 h. The 
crude product was purified by chromatography on silica gel (CH2Cl2/MeOH 95/5) and then treated 
to eliminate remaining DMSO according to general procedure 4 to provide the expected compound 
as a whitish foamy solid (0.91 g, 2.45 mmol, 81%). Mp: 91-93 ºC (heptane/benzene); 1H-NMR (300 
MHz, CDCl3): δ = 3.68 (s, 6H, OCH3-C3’, OCH3-C5’), 3.69 (s, 3H, OCH3-C4’), 3.77 (s, 3H, OCH3-
C4”), 4.14 (s, 2H, CH2), 5.77 (br. s, 1H, OH), 6.36 (s, 2H, H-2’, H-6’);  6.90 (d, J = 8.0 Hz, 1H, H-
5”), 7.02 (d, J = 1.7 Hz, 1H,  H-2’’), 7.22 (dd, J1 = 8.0 Hz, J2 = 1.7 Hz, 1H, H-6”); 13C-NMR (75 
MHz, CDCl3): δ = 31.7 (CH2, CH2-Ar), 56.2 (CH3, OCH3-C4)’  56.4 (CH3 x 2, OCH3-C3’, OCH3-
C5’), 61.3 (CH3, OCH3-C3”), 105.8 (CH x 2, C-2’, C-6’), 110.9 (CH, C-2”), 115.2 (CH, C-5”), 121.2 
(CH, C-6”), 122.4 (C, C-5), 134.7 (C, C-1’’), 136.7 (C x 2, C-1’, C-4’), 146.5 (C, C-4’’), 147.4 (C, 
C-4), 153.6 (C x 3, C-3’, C-5’, C-3”); IR (NaCl): υ’ 3540 (OH), 3440 (NH), 1593 (C=C), 1240 (Ar-
O), 1130 (C-O) cm-1; MS (ESI(+)): m/z 394 [M+Na]+. HRMS (ESI): m/z 372.1574 [M+H]+, 
C19H22N3O5 requires 372.1559. 
 
4.1.4.8.  4-(3-Indolemethyl)-5-(3,4,5-trimethoxyphenyl)-1,2,3-triazole (21). 
 
General procedure 4.1.4. was applied to 1-(3-indolemethyl)-2-(3,4,5-trimethoxybenzyl)-1-
nitroethene (13) (1.00 g, 2.70 mmol) with a reaction time of 12 h. The crude product was purified 
by chromatography on silica gel (CH2Cl2/MeOH 95/5) and then treated to eliminate remaining 
DMSO according to general procedure 4 to provide the expected compound as a brown solid (0.92 
g, 2.52 mmol, 93%). Mp: 122-123 ºC (benzene/acetone); 1H-NMR (300 MHz, CDCl3): δ = 3.52 (s, 
6H, OCH3-C3’, OCH3-C5’), 3.83 (s, 3H, OCH3-C4’), 4.28 (s, 2H, CH2), 6.67 (s, 1H, H-2”), 6.82 (s, 
2H, H-2’, H-6’), 7.12 (t, J = 7.4 Hz, 1H, H-6”), 7.18 (t, J = 7.4 Hz, 1H, H-5”), 7.29 (d, J = 8.0 Hz, 
1H, H-7”), 7.52 (d, J = 8.2 Hz, 1H, H-4”), 8.17 (s, 1H, NH indole); 13C-NMR (75 MHz, DMSO): 
δ = 22.6 (CH2, CH2-Ar), 55.9 (CH3 x 2, OCH3-C3’, OCH3-C5’), 60.5 (CH3, OCH3-C4’), 104.8 (CH x 
2, C-2’, C-6’), 111.9 (C, C-3”), 112.4 (C, C-3”a), 118.8 (CH x 2, C-5”, C-6”), 121.8 (CH, C-2”), 
123.6 (CH, C-4”), 127.2 (CH, C-7”), 133.0 (C, C-1’), 136.7 (C, C-5), 142.8 (C, C-7”a), 143.8 (C, 
C-4), 153.7 (C x 3, C-3’, C-4’, C-5’); IR (NaCl): υ’ 3478 (NH-indole), 3009 (NH), 1589 (C=C), 
1239 (Ar-O), 1128 (C-O) cm-1; HRMS (ESI): m/z 365.1625 [M+H]+, C20H21N4O3 requires 
365.1614. 
 
4.1.5.  5-(3-Amino-4-methoxyphenyl)-4-(3,4,5-trimethoxybenzyl)-1,2,3-triazole (22).  
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Compound 22 was obtained by reduction of the nitro group in 17 (0.43 g, 1.07 mmol) via 
catalytic hydrogenation with a reaction time of 1 h, using 10% w/w of Pd/C as a catalyst and THF 
as the solvent. The reaction mixture was filtered over a Celite surface to eliminate the Pd/C and 
thoroughly rinsed with acetone. The solvents were then evaporated under vacuum and the crude 
product was purified by chromatography on silica gel (CH2Cl2/MeOH 96/4) to provide the expected 
compound as a bright white foamy solid (0.35 g, 0.94 mmol, 88%). Mp: 112-113 ºC 
(benzene/acetonitrile); 1H-NMR (300 MHz, CDCl3): δ = 3.74 (s, 6H, OCH3-C3’, OCH3-C5’), 3.80 (s, 
3H, OCH3-C4”), 3.86 (s, 3H, OCH3- C4’), 4.15 (s, 2H, CH2-Ar), 6.40 (s, 2H, H-2’, H-6’), 6.79 (d, J 
= 8.0 Hz, 1H, H-5”), 6.92 (dd, J1 = 8.0 Hz, J2 = 2.0 Hz, 1H, H-6”), 6.98 (d, J = 2.0 Hz, 1H, H-2”); 
13C-NMR (75 MHz, CDCl3): δ = 31.5 (CH2, CH2-Ar), 55.6 (CH3, OCH3-C4”), 56.2 (CH3 x 2, 
OCH3-C3’, OCH3-C5’), 61.0 (CH3, OCH3-C4’), 105.5 (CH x 2, C-2’, C-6’), 110.5 (CH, C-5”), 114.4 
(CH, C-2”), 118.1 (CH, C-6”), 122.8 (C, C-1”), 134.4 (C, C-1’), 136.5 (C x 2, C-4, C-5), 143.1 (C, 
C-3”), 147.7 (C, C-4”), 153.2 (C x 3, C-3’, C-4’, C-5’); IR (NaCl): υ’ 3007 (NH), 1592 (C=C), 
1240 (Ar-O), 1129 (C-O) cm-1; HRMS (ESI): m/z 371.1729 [M+H]+, C19H22N3O5 requires 
371.1719. 
 
4.2. Biological evaluation procedures 
 
4.2.1. Endothelial cell morphology.  
 
To assess the effects of the compounds on the morphology of endothelial cells, we used the EAhy 
926 endothelial cell line which is derived from the fusion of human umbilical vein endothelial cells 
(HUVEC) with the permanent human cell line A549 [55]. The EAhy 926 cell line is considered as 
one of the best immortalized HUVEC cell lines because these cells express most of the biochemical 
markers of parental HUVEC EAhy 926 cells [56]. EAhy 926 cells were grown in DMEM 
containing 2 mM L-glutamine, 10% fetal bovine serum, 100 U/mL penicillin and 100 µg/mL 
streptomycin (37°C, 5% CO2). Exponentially growing EAhy 926 cells were plated onto 96 well 
plates at 5000 cells/100 µL/well. Twenty-four hours after plating, the medium was aspirated, and 
100 µL of medium containing the test compound was added to the well containing the cells (in 
triplicate) and incubated for 2 h (37°C, 5% CO2). The highest concentration used was 100 µM 
followed by serial two-fold dilutions down to low nanomolar concentrations, if needed for the most 
morphologically active compounds. After the 2 h-incubation period, digital photographs were taken 
of representative centre areas of each well at a magnification of 100 X and 200 X. The results are 
presented as the minimum concentration that could elicit the rounding up of more than 15% of cells 
in a field in order to exclude normal mitotic cells which is less that 15% in control 1% DMSO 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 20 
treated cells. Triplicate concentrations on the same plate were routinely carried out. CA4 was 
included in the experiments as internal standard. 
 
4.2.2. Inhibition of tubulin polymerization.  
 
Tubulin microtubule assembly in microtubules was carried out using the fluorescent dye DAPI 
(4',6-diamidino-2-phenylindole) [57] in a 96-well plate format as described [58, 59]. The standard 
assay was performed as follows: wells were charged with tubulin (Cytoskeleton, 97% pure, final 
concentration 1 mg/ml) in PME buffer (100 mM PIPES (1,4-piperazinebis(ethanesulfonic acid); 1 
mM MgSO4; 2 mM EGTA) with 10 µM DAPI and varying concentrations of the test compounds 
using colchicine at 30 µM as an internal positive control. The final concentrations used for the test 
compounds were started at 30 µM and diluted in 3-fold decrements thereafter until no inhibition 
was observed. Triplicate wells were run for each concentration. After a preincubation of 45 min at 
room temperature, 5 µl of 1 mM GTP was added to each well to initiate tubulin polymerization, and 
the plate was then transferred to a thermostated Victor plate reader at 37 °C for an additional 2 h. 
Fluorescence was then read at the excitation wavelength of 360 nm and emission of 450 nm. The 
percent inhibition was determined as follows: 1 - (∆F(sample/∆F(control) X 100, where ∆F control 
= F(no inhibition) - F(complete inhibition), and ∆F sample = F(sample) - F(complete inhibition 
with colchicine). The IC50 for compound-induced inhibition of tubulin polymerization is the 
concentration at which the extent of inhibition of polymerization is 50% of the maximum value as 
determined from the semi-logarithmic plot of percent inhibition as a function of the logarithm of 
drug concentration fitted to a sigmoidal model with variable slope using the nonlinear regression 
program SigmaPlot (Jandel Scientific). In these conditions the IC50 value for colchicine inhibition 
of tubulin polymerization was 0.36 µM. 
 
4.2.3 Cytotoxicity assay.  
 
Murine B16 melanoma cells were grown in DMEM medium containing 2 mM L-glutamine, 10% 
foetal bovine serum, 100 U/mL penicillin and 100 µg/mL streptomycin (37°C, 5% CO2). All 
compounds were initially dissolved in DMSO at a stock concentration of 2.5 mg/mL and were 
further diluted in cell culture medium. Exponentially growing cells were plated onto 96-well plates 
at 5000 cells per well in 100 µl of culture medium. Twenty-four h after plating, 100 µl of medium 
containing the compound at final concentrations ranging from 0.01 to 100 µM were added to the 
wells (in triplicate) containing the cells, and incubated for 48 h at 37 °C and 5% CO2. After the 48 h 
exposure period to the test compounds, cell viability was assayed using the MTT test [60] and 
absorbance was read at 562 nm in a microplate reader (BioKinetics Reader, EL340). Appropriate 
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controls with DMEM only and MTT were run to subtract background absorbance. The 
concentration of compound that inhibited cell viability by 50% (inhibitory concentration for 50% of 
cells, or IC50) was determined using the GraphPad Prism software. 
 
4.2.4 Docking protocol 
 
Our previous docking work on analogues of Combretastatin A4 [47] implied GOLD (Genetic 
Optimisation for Ligand Docking), so we performed our study with this software in its new version 
[50]. 
Ligands preparation 
Three compounds, CA4, 11 and 19 were initially built within MarvinSketch 5.8.0 from Chemaxon 
[61] next submitted to Corina [62], a 3D structure generator. Obtained 3D conformations were next 
submitted to Ligprep from the Schrödinger software suite [63] in order to generate tautomers forms. 
Regarding a pH=7.0 +/-2.0 three forms were found for 19 where H atom can be bound to the three 
N atoms of the triazole ring. Due to the high level of flexibility of the previously structures 
conformational analyses, according to the OPLS2005 force field [64], were computed and the 
lowest energy conformations were kept as input for the docking stage. 
Protein preparation 
3D structure of tubulin was retrieved from the Protein Data Bank (http://www.rcsb.org, PDB ID: 
1SA0) [46]. Subunits C, D and E were removed. Only subunits A, B, corresponding to the 
colchicine binding site, and small molecules DAMA-colchicine (CN2), GTP and Mg2+ ion in this 
site were conserved. 
Molecular docking 
Docking runs were performed with an exploration of the conformational space of ligands more 
important than with default parameters in that sense that 100 conformations were kept for each 
ligand and early termination process (run will stop after 3 conformations found within an RMSD of 
1.5 Å) was disabled. Goldscore was chosen again as our fitness scoring function. 
 
 
4.2.5 Antitumor evaluation in mice.  
 
Female BALB/cJRj mice (average weight, 18 g) obtained from Janvier (Le Genest St Isle, France) 
were supplied food and water ad libitum. Colon 26 tumor fragments (30 to 60 mg) were implanted 
bilaterally in the axillary region by subcutaneous injection on day 0 with a 12 gauge trocar [65]. 
Bilateral implants were used to insure a more uniform tumor burden per mouse. The methods of 
protocol design, chemotherapy techniques, and data analysis have been presented in detail 
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elsewhere [66, 67]. Briefly, the animals were pooled before distribution to the various treatment 
and control groups (5 mice per group) and preliminary experiments in non tumored animals allowed 
to determine the maximum tolerated dose which was 150 mg/kg for 11 and 100 mg/kg for 19, when 
administered intraperitoneally for two weeks on days 3-7 and 10-14 after tumor implantation (day 
0). Compounds were freshly prepared daily in saline containing 5% DMSO and 5% polysorbate 80 
and injected intraperitoneally in a volume of 0.2 ml. Mice were weighed daily and checked for 
clinical signs of toxicity. Tumors were measured daily with a caliper and tumor volumes (mm3) 
were estimated from two dimensional tumor measurements (mm): Tumor volume (mm3) = (length 
× width 2 × 0.5). The end points used to determine the antitumor activity were the percent T/C value 
and the tumor growth delay (T-C value). The %T/C was calculated when the tumor volume reached 
1500 mm3 for the controls (C). The T/C value in percent is calculated as follows: T/C (%) = 
(median tumor weight of the Treated / median tumor weight of the Control) × 100. According to the 
National Cancer Institute (NCI) standards, a T/C of 42% is the minimum level for activity. The 
tumor growth delay (T-C value) was calculated based on the median time (in days) required for the 
treatment group (T) and the control group (C) tumors, to reach the size of 1500 mm3.  
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Legends for Figures 
 
Figure 1. Morphological effects on endothelial cells. Typical rounding up of endothelial cells 
(EAhy 926) exposed to CA4 1 (0.006 µM) and compound 19 (1 µM) for a 2 hour exposure time. 
The solvent DMSO 1% was used as the control. Original magnification, 200 X.  
 
Figure 2. Correlation between rounding up activity on endothelial cells and inhibition of 
tubulin polymerization (ITP). Compounds with good morphological activity (rounding up 
concentration <10 µM) are plotted against the concentration needed to inhibit tubulin 
polymerization by 50% (IC50). Equation of the straight line: Y=4.396X, r² =0.834. 
 
Figure 3. Putative binding of our best cis-constrained analogues of CA4. For clarity non polar 
hydrogen atoms are not represented. 
Top: CA4 docking pose (green stick model) is superimposed to crystallographic CN-2 (dama-
colchicine, gray stick model), reproducing the binding mode highlighted in the colchicine domain 
of the crystallographic complex (PDB ID: 1SA0). α and β-tubulin are ribbons displayed according 
to their secondary structure. Residues of the three zones of interaction [49] are represented too 
(zone 1: cyan, zone 2: orange, zone 3: green). Val181 α from zone 1 and Cys241 β from zone 2 are 
highlighted (tube, element colored) as they are involved in H bonds represented in yellow dashed 
lines. 
Down: superimposition of CA4 (green tube), 11 (pink tube) and the best docking scored tautomer of 
19 (grey tube). Concerning the compound 19, similar conformations, not shown, were obtained 
regardless the tautomer forms. The right part represents a 90° rotation about the vertical axis of the 
left view and highlights the conservation of the cisoid arrangement of the two aromatic rings. 
 
Figure 4. Antitumor effects of compounds 11 and 19. Mice bearing subcutaneously implanted 
colon 26 carcinoma tumors were treated intraperitoneally with solvent (Control) or with compound 
11 or 19 for 2 weeks on days 3 to 7, and days 10 to 14, as describe in the Experimental protocols 
section. 
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